Lathrop GPM assisted client Diagonal Therapeutics with its successful, $125 million Series B financing round. Intellectual property partners James Velema and Mike Spellberg, Ph.D., advised Diagonal on the biotechnology company’s IP strategy and implementation.
Lathrop GPM has represented Diagonal Therapeutics since the company’s formation, advising the company through its seed funding and a previous Series A funding that raised $128 million to accelerate development of its differentiated scientific approach. Lathrop GPM’s work has focused on building and protecting a robust global portfolio of intellectual property assets, aligned with Diagonal’s long-term research and development objectives.
The proceeds of the Series B financing round will fund clinical development of DIAG723 and advance additional clustering antibody drug candidates. Expected to enter clinical development during the first half of 2026, DIAG723 is a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension. The Series B financing further strengthens Diagonal’s ability to advance its pipeline and expand its platform capabilities as it moves toward clinical development.
Diagonal Therapeutics is a biotech company advancing novel disease-modifying clustering antibodies that repair dysregulated signaling implicated in a range of illnesses. The company’s DIAGONAL Product Engine combines proprietary computational and experimental techniques to overcome historical challenges associated with antibody drug discovery and efficiently deliver optimized therapeutic assets. Diagonal’s pipeline comprises clustering antibodies designed to selectively address the underlying cause of disease across hematology, hepatology, and nephrology, offering the potential to deliver life-changing therapies for patients. For more information, visit www.diagonaltx.com.